Skandinaviska Enskilda Banken Ab (Publ) Inozyme Pharma, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $22.4 Billion
- Q2 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 377,227 shares of INZY stock, worth $1.51 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
377,227Holding current value
$1.51 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding INZY
# of Institutions
85Shares Held
48.7MCall Options Held
162KPut Options Held
0-
Beryl Capital Management LLC Redondo Beach, CA6.32MShares$25.3 Million3.83% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$18 Million16.98% of portfolio
-
Glazer Capital, LLC New York, NY4.33MShares$17.3 Million0.62% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$17.1 Million1.16% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$13.4 Million0.0% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $161M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...